Our Mission
We are relentless in our pursuit of improving the lives of people impacted by endocrine and neurological disorders. We listen, and place the unique needs of patients and families at the forefront of all we do.
Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need.
Our product candidate, tildacerfont, is a second-generation CRF1 receptor antagonist currently in trials in adult and pediatric patients with classic congenital adrenal hyperplasia (CAH). We aim to advance the treatment paradigm for classic CAH with a well-tolerated, non-steroidal approach designed to offer markedly improved disease control and reduced steroid burden for patients.
Tildacerfont may also benefit patients with other disorders characterized by elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol, including polycystic ovary syndrome (PCOS).
Spruce Bio is also developing tildacerfont as a precision treatment for major depressive disorder (MDD). Spruce is collaborating with HMNC Brain Health to use their precision diagnostic tool, Cortibon, to identify patients most likely to respond to treatment. Tildacerfont has the potential to mediate responses to stress, which has the potential to address up to 50% of the MDD patients worldwide using Cortibon.
